Technavio has published a new report on the global acute ischemic stroke therapeutics market from 2017-2021. (Graphic: Business Wire)

The research study covers the present scenario and growth prospects of
the global AIS
therapeuticsmarketfor 2017-2021. Technavio presents
a detailed picture of the market by way of study, synthesis, and
summation of data from multiple sources.

As per the National Institutes of Health (NIH), AIS is the fourth
leading cause of death and the most common cause of adult disability in
the US. The most common cause of AIS is the obstruction of blood
vessels, resulting in decreased oxygen-rich blood supply to a section of
the brain, thereby leading to severe damage of neurons. The damaged
neurons lead to the corresponding loss of neurological functions, thus
requiring immediate medical treatment.

Technavio’s sample reports are free of charge and contain multiple
sections of the report including the market size and forecast, drivers,
challenges, trends, and more.

Rising prevalence of disease

Cardiovascular diseases, particularly MI and stroke, are the leading
causes of disability and death globally and are a major public health
concern. AIS is the most common form of stroke that occurs when
oxygen-rich blood supply to a part of the brain is blocked either by the
formation of plaque or a blood clot.

Sapna Jha, a lead cardiovascular
and metabolic disorders research analyst at Technavio, says,
“With the increasing cases of ischemic stroke, the healthcare community
is gaining a better understanding of the pathophysiology of this
disease. Additionally, the rise in the prevalence rate and subsequently,
the incidence rate of disease, has led to the increase in consumption of
AIS therapeutics, such as ACTIVASE, thereby driving the market growth.”

Increasing adoption of NOACs

The increasing adoption of NOACs among physicians is expected to drive
the market growth. NOACs, such as dabigatran, rivaroxaban, and apixaban
exert their pharmacological effects by either directly targeting
thrombin or by inhibiting factor Xa, thereby preventing the formation of
thrombus. They provide rapid onset of action and do not require regular
coagulation monitoring.

“NOACs are gradually replacing the traditional anticoagulants.
Further, with the introduction of anticoagulant antidotes such as
idarucizumab in the market, the acceptance of NOACs will increase, as
the risk of bleeding will be eliminated. The global AIS therapeutics
market is thus shifting from a single injectable anticoagulant to highly
competitive NOACs. Some NOACs that are increasingly preferred by
physicians include Xarelto from Bayer and Fragmin from Pfizer,” adds
Sapna.

Increasing prevalence of sedentary lifestyles

As per the CDC, more than 36% of US adults have obesity. The concept of
sedentary lifestyle leading to obesity is no stranger to the global
cardiovascular disorders treatment market. The increasing prevalence of
cardiovascular diseases in developed and other developing countries can
be attributed to the increasing adoption of sedentary lifestyles
accompanied by poor diet.

Persistent ischemic condition leads to cell death or apoptosis and the
loss of corresponding cell function. For instance, in AIS, ischemia
leads to necrosis of neurons and the loss of corresponding neurological
function. If not treated on time, it can lead to death. Hence, immediate
treatment with AIS therapeutics is required, which, in turn, drives the
market growth.

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.